Welcome and Introduction
Cardiometabolic Comorbidities in Psoriasis: Bridging the Evidence to Practice Gap
Álvaro González-Cantero, MD, PhD, Spain
Global Healthcare Study on Psoriasis: Achievements and Perspectives
Julia-Tatjana Maul, MD, Switzerland
Psoriasis and Tuberculosis in the Era of New Biologic Therapies
Tiago Torres, MD, PhD, Portugal
Small Molecules in Psoriasis: Do Big Things Come in Small Packages?
Lluís Puig, MD, PhD, Spain
Psoriasis and Sexual Impairment
Anna López Ferrer, MD, PhD, Spain
The Psoriasis – Atopic Dermatitis Spectrum: Overlapping Forms: The Next Frontier
José Manuel Carrascosa, MD, PhD, Spain
Q & A and Closing Comments
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
